Skip to content

Bone density gains differed between treatments in women with diabetes and osteoporosis

In the diabetes subgroup, rhPTH improved lumbar spine bone density more than alendronate; fracture outcomes were not reported.

By 100HP editorialAbstract-based explanation checked

Based on the published abstract. The full paper may contain additional methods, results and limitations.

The 30-second takeaway

Among postmenopausal patients who had both osteoporosis and diabetes, rhPTH improved lumbar spine bone mineral density more than alendronate. This was a finding about bone density in a specific clinical subgroup. The abstract does not report fracture outcomes, so the result cannot show whether either treatment prevented more fractures or provided greater overall clinical benefit.

Keep in mind

The human trial was open-label and conducted at one center. The abstract does not provide participant counts, numerical treatment differences, confidence intervals or adverse-event results, limiting assessment of the reported advantage.

THE RESULT, WITH CONTEXT

What researchers found

Greater improvement

Lumbar spine bone mineral density

After 1 year, rhPTH versus alendronate in patients with osteoporosis and diabetes; no numerical effect estimate was reported.

Front Endocrinol (Lausanne), 2025 · Original source ↓

Bone turnover was also studied

Patients with both conditions started with lower levels of markers of bone turnover. In mice with diabetes, rhPTH reversed low turnover and improved several structural bone measures; those animal results remain separate from the human findings.

The comparison depended on subgroup

Alendronate produced less lumbar spine improvement in patients with diabetes than in those with osteoporosis alone. The abstract does not report the same rhPTH advantage across every participant group, or across all skeletal sites.

CHECK THE ORIGINAL

The original publication

Effect of rhPTH(1-34) and alendronate on the treatment of type 2 diabetic bone disease.

Li H, Yuan L, Liu P et al.
Front Endocrinol (Lausanne) · 2025

PubMed ID
41030855
Record checked

AI-assisted research and writing. This explains one selected publication; it is not a complete review of everything known. Our approach.